(Q37256836)

19 August 2017

1 reference

title

Anti-EGFR monoclonal antibodies in metastatic colorectal cancer: time for an individualized approach? (English)

1 reference

19 August 2017

1 reference

1 reference

metastatic colon cancer

1 reference

1 reference

1 reference

Marwan Fakih

1

1 reference

19 August 2017

publication date

1 September 2008

1 reference

Expert Review of Anticancer Therapy

19 August 2017

published in

1 reference

19 August 2017

volume

8

1 reference

19 August 2017

issue

9

1 reference

19 August 2017

page(s)

1471-1480

1 reference

Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer

19 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.9.1471

Bleomycin in testicular cancer: will pharmacogenomics improve treatment regimens?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.9.1471

Capecitabine and irinotecan as first-line treatment of advanced colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.9.1471

Cetuximab-induced hypomagnesemia in patients with colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.9.1471

Magnesium wasting associated with epidermal-growth-factor receptor-targeting antibodies in colorectal cancer: a prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.9.1471

Overall survival of patients with advanced colorectal cancer correlates with availability of fluorouracil, irinotecan, and oxaliplatin regardless of whether doublet or single-agent therapy is used first line

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.9.1471

Hepatic resection after rescue cetuximab treatment for colorectal liver metastases previously refractory to conventional systemic therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.9.1471

Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.9.1471

Cetuximab for the treatment of colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.9.1471

K-ras oncogene mutations in sporadic colorectal cancer in The Netherlands Cohort Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.9.1471

Kirsten ras mutations in patients with colorectal cancer: the 'RASCAL II' study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.9.1471

Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.9.1471

KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.9.1471

KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.9.1471

Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.9.1471

KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.9.1471

Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.9.1471

PTEN loss of expression predicts cetuximab efficacy in metastatic colorectal cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.9.1471

Pharmacogenetic profiling for cetuximab plus irinotecan therapy in patients with refractory advanced colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.9.1471

Specific codon 13 K-ras mutations are predictive of clinical outcome in colorectal cancer patients, whereas codon 12 K-ras mutations are associated with mucinous histotype

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.9.1471

Nuclear Factor-kB Tumor Expression Predicts Response and Survival in Irinotecan-Refractory Metastatic Colorectal Cancer Treated With Cetuximab-Irinotecan Therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.9.1471

10.1586/14737140.8.9.1471

21 January 2018

Identifiers

DOI

1 reference

19 August 2017

1 reference